Editas Stock Soars 7% After Its Quarterly Loss Narrows And Collaboration Revenue Rises

The gene-editing developer projects cash lasting into the second half of 2028 and has Australian clearance to begin an early-stage trial.

Share
Editas Stock Soars 7% After Its Quarterly Loss Narrows And Collaboration Revenue Rises

Editas Medicine, which develops CRISPR gene-editing medicines, soared 7.39% to $2.76 in Monday trading, as of 12:03 PM ET, adding $29 million in market value after reporting a smaller quarterly loss and higher collaboration revenue. Monday's SEC filing showed the third-quarter net loss shrinking from the year-earlier $25.1 million to $23.4 million.

Partner Milestones Lift Revenue

Third-quarter collaboration and research revenue exceeded the year-earlier $7.5 million, totaling $10.4 million. The higher revenue accompanied a narrower loss, but Editas remained unprofitable.

The earlier quarter showed the same divide between revenue growth and profitability. For the quarter ended June 30, Editas reported revenue of $11.9 million, up 232.3% year over year, and a net loss of $18.2 million.

Australian Clearance And Cash Runway

Editas also outlined Australian clearance to begin an early-stage trial for an inherited condition that causes elevated cholesterol. Its lead program, EDIT-401, is designed as an experimental, one-time treatment to lower LDL cholesterol in people with elevated levels.

The company projects that its cash and investments of $190.2 million will support operations into the second half of 2028.

Editas focuses on treatments that edit DNA inside the patient's body. Its research also includes editing blood stem cells to treat sickle cell disease and transfusion-dependent beta thalassemia. Licensing CRISPR patents and working with other drug developers bring in revenue.

A Rebound Below The High

EDIT shares were on pace for their biggest one-day gain since Wednesday in Monday trading, as of 12:03 PM ET. Editas had a total market value of about $424 million in Monday trading, as of 12:03 PM ET.

The rebound still left Editas shares 30% below their 52-week high in Monday trading, as of 12:03 PM ET.

Australian clearance lets Editas begin the early-stage cholesterol trial; the company's projected funding horizon reaches the second half of 2028.

Sources

More on Editas Medicine

All Editas Medicine (EDIT) coverage →